All Q2 FY26 results →

MC

McKesson Corporation

Q2 FY26Health Care Providers and Services

McKesson Corporation Q2 FY26 Results — Earnings Call Analysis

Q2 FY26 earnings call: what management said on revenue, margins and capex.

Price₹757

Market cap₹91.0K Cr

P/E19.6

Updated29 May 2026

Read4 min read

What the Q2 FY26 call signalled

2 of 4 strong

RevenueModerate growth

MarginMargins steady

CapexCapex planned

FundraiseFundraise planned

The short version

- Overall revenue growth for fiscal 2027 is guided at 5% to 9%, with adjusted operating profit growth of 8% to 12%. - Fiscal 2027 adjusted earnings per diluted share (EPS) guidance range: $43.80 to $44.60, representing 12% to 14% year-over-year growth.

From McKesson Corporation's Q2 FY26 earnings-call transcript · updated 29 May 2026.

Revenue & Sales Performance

Moderate growth

Overall revenue growth for fiscal 2027 is guided at 5% to 9%, with adjusted operating profit growth of 8% to 12%.
North American Pharmaceutical segment: revenue expected to increase 4% to 8%, supported by stable prescription volume growth and specialty product distribution, including GLP-1 category growth.
Oncology and Multispecialty segment: strong revenue growth anticipated, 14.5% to 18.5%, driven by expanded provider networks, acquisitions (PRISM and Core Ventures), and increased specialty distribution volumes.
Prescription Technology Solutions segment: revenue growth of 2.5% to 6.5%, with demand strong for access and affordability solutions, particularly specialty therapies.
Stable utilization trends expected, with specialty prescriptions and innovative therapies driving growth.

2 more points from McKesson Corporation's call on revenue

Create a free account to keep reading this call

Profitability & Margins

Fiscal 2027 adjusted earnings per diluted share (EPS) guidance range: $43.80 to $44.60, representing 12% to 14% year-over-year growth.
Excluding certain gains in fiscal 2026, fiscal 2027 EPS growth is 14% to 16%, at the upper end of the long-term target range.
Long-term adjusted earnings per diluted share growth target: 13% to 16%.
Long-term adjusted segment operating profit growth targets:
North American Pharmaceutical: 5% to 8%
Oncology and Multi-specialty: 13% to 16%
Prescription Technology Solutions: 10% to 13%

2 more points from McKesson Corporation's call on margins

Create a free account to keep reading this call

See what McKesson Corporation said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

Capex planned

Fiscal 2026 capital expenditures totaled $745 million, focusing on distribution technology and infrastructure to support future growth.
Investments continue to advance technology-enabled services, enhancing product functionality, customer experience, and automation.
Launch of a state-of-the-art Montreal distribution center featuring AI-powered storage/retrieval systems to expand capacity and improve resiliency.
Implementation of AI-driven inventory planning systems for end-to-end real-time decision making, contributing to working capital savings.
Ongoing investments in operational efficiency and infrastructure improvements to drive long-term growth in North American Pharmaceutical segment.
Continued deployment of technology in Oncology and Multispecialty segments, including ambient scribe technology and automation to improve provider productivity.

2 more points from McKesson Corporation's call on capex

Create a free account to keep reading this call

Fundraising & Capital Structure

In early April, McKesson established an independent capital structure for its Medical Surgical Solutions segment by issuing a $1 billion revolving credit facility and $1 billion in Term Loan A facilities.
McKesson plans to issue up to $2.25 billion in additional term loans in the second half of the first quarter of fiscal 2027 to support the Medical Surgical Solutions separation.
Apollo Funds is acquiring approximately a 13% minority interest in Medical Surgical Solutions through a $1.25 billion strategic investment, valuing the business at around $13 billion.

2 more points from McKesson Corporation's call on fundraising

Create a free account to keep reading this call

See what McKesson Corporation said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

From the discussion, the following points are noted that indirectly relate to business momentum and growth outlook: - Strong business momentum with specialty pharmaceutical distribution growth, oncology and multispecialty expansion. - Revenue growth guidance for fiscal 2027: 5% to 9% overall, 1% to 6% for Medical Surgical Solutions. - Continued provider expansion with more than 570 new providers added in the U.S. oncology network in fiscal ’26.

2 more points from McKesson Corporation's call on order book

Create a free account to keep reading this call

Others in Health Care Providers and Services this season

BrightSpring Health Services, Inc. (Q2 FY26)
BrightSpring Health Services, Inc. Q2 FY26 quarterly results analysis. Pharmacy Solutions expected to see balanced sequential revenue and EBITDA growth througho
DaVita Inc. (Q2 FY26)
DaVita Inc. Q2 FY26 quarterly results analysis. Treatment volume guidance raised from flat to 25-50 basis points growth for 2026, driven by better underlying pe
Tenet Healthcare Corporation (Q2 FY26)
Tenet Healthcare Corporation Q2 FY26 quarterly results analysis. Hospital segment expects a 10% normalized year-over-year adjusted EBITDA growth in 2026, suppor
Guardant Health, Inc. (Q2 FY26)
Guardant Health, Inc. Q2 FY26 quarterly results analysis. Sales team started this year with ~300 reps; incremental gross profit will be reinvested in expanding

Compare:vs UnitedHealth Group Incorporated vs Elevance Health, Inc.vs HCA Healthcare, Inc.

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

McKesson Corporation and 15K+ more earnings calls,
for less than your morning chai

a day

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What were McKesson Corporation Q2 FY26 results?

- Overall revenue growth for fiscal 2027 is guided at 5% to 9%, with adjusted operating profit growth of 8% to 12%. - Fiscal 2027 adjusted earnings per diluted share (EPS) guidance range: $43.80 to $44.60, representing 12% to 14% year-over-year growth.

What is McKesson Corporation share price analysis?

McKesson Corporation currently shows a below-average growth signal. The stock trades at a P/E of 19.6 with a market cap of $90,992. Investors should review the full earnings analysis for detailed insights.

Is McKesson Corporation planning capital expenditure?

- Fiscal 2026 capital expenditures totaled $745 million, focusing on distribution technology and infrastructure to support future growth.

Keep McKesson Corporation on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.